Morgan Stanley’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.38M | Buy |
4,509,962
+3,511,117
| +352% | +$7.71M | ﹤0.01% | 3739 |
|
|
2026
Q1 | $2.44M | Buy |
998,845
+295,707
| +42% | +$593K | ﹤0.01% | 4630 |
|
|
2025
Q4 | $963K | Sell |
703,138
-596,028
| -46% | -$786K | ﹤0.01% | 5205 |
|
|
2025
Q3 | $1.61M | Buy |
1,299,166
+690,197
| +113% | +$823K | ﹤0.01% | 4913 |
|
|
2025
Q2 | $688K | Sell |
608,969
-1,744,132
| -74% | -$2.32M | ﹤0.01% | 5302 |
|
|
2025
Q1 | $3.44M | Buy |
2,353,101
+1,354,505
| +136% | +$2.55M | ﹤0.01% | 4227 |
|
|
2024
Q4 | $2.13M | Sell |
998,596
-722,934
| -42% | -$1.78M | ﹤0.01% | 4653 |
|
|
2024
Q3 | $4.82M | Sell |
1,721,530
-435,432
| -20% | -$1.16M | ﹤0.01% | 3987 |
|
|
2024
Q2 | $5.03M | Sell |
2,156,962
-75,002
| -3% | -$221K | ﹤0.01% | 3869 |
|
|
2024
Q1 | $9.98M | Buy |
2,231,964
+564,138
| +34% | +$2.35M | ﹤0.01% | 3353 |
|
|
2023
Q4 | $5.35M | Buy |
1,667,826
+286,108
| +21% | +$811K | ﹤0.01% | 3857 |
|
|
2023
Q3 | $4.38M | Buy |
1,381,718
+50,281
| +4% | +$220K | ﹤0.01% | 3854 |
|
|
2023
Q2 | $6.62M | Buy |
1,331,437
+349,962
| +36% | +$1.89M | ﹤0.01% | 3548 |
|
|
2023
Q1 | $4.85M | Buy |
981,475
+130,996
| +15% | +$840K | ﹤0.01% | 3815 |
|
|
2022
Q4 | $5.35M | Buy |
850,479
+234,460
| +38% | +$2.17M | ﹤0.01% | 3697 |
|
|
2022
Q3 | $6.65M | Sell |
616,019
-521,246
| -46% | -$7.08M | ﹤0.01% | 3404 |
|
|
2022
Q2 | $13M | Sell |
1,137,265
-551,176
| -33% | -$4.89M | ﹤0.01% | 2787 |
|
|
2022
Q1 | $15.4M | Buy |
1,688,441
+422,386
| +33% | +$4.4M | ﹤0.01% | 2406 |
|
|
2021
Q4 | $18.9M | Buy |
1,266,055
+203,029
| +19% | +$3.58M | ﹤0.01% | 2220 |
|
|
2021
Q3 | $27.3M | Sell |
1,063,026
-66,452
| -6% | -$1.58M | ﹤0.01% | 1774 |
|
|
2021
Q2 | $29.5M | Buy |
1,129,478
+1,035,898
| +1,107% | +$29.5M | ﹤0.01% | 1756 |
|
|
2021
Q1 | $3.3M | Sell |
93,580
-249,202
| -73% | -$8.41M | ﹤0.01% | 3838 |
|
|
2020
Q4 | $8.65M | Buy |
342,782
+142,367
| +71% | +$4.64M | ﹤0.01% | 2667 |
|
|
2020
Q3 | $7.56M | Buy |
200,415
+153,345
| +326% | +$5.78M | ﹤0.01% | 2296 |
|
|
2020
Q2 | $2.02M | Sell |
47,070
-259
| -0.5% | -$9.37K | ﹤0.01% | 3590 |
|
|
2020
Q1 | $920K | Sell |
47,329
-32,837
| -41% | -$782K | ﹤0.01% | 4020 |
|
|
2019
Q4 | $2.08M | Buy |
80,166
+48,492
| +153% | +$1.34M | ﹤0.01% | 4005 |
|
|
2019
Q3 | $864K | Buy |
31,674
+21,967
| +226% | +$626K | ﹤0.01% | 4382 |
|
|
2019
Q2 | $260K | Buy |
9,707
+691
| +8% | +$19.3K | ﹤0.01% | 4913 |
|
|
2019
Q1 | $260K | Sell |
9,016
-27,715
| -75% | -$804K | ﹤0.01% | 4919 |
|
|
2018
Q4 | $990K | Buy |
+36,731
| New | +$976K | ﹤0.01% | 4283 |
|
Other funds holding ALLO
P
FLSM
TGA
SCM
Morgan Stanley's ALLO Position: Q2 2026 in Review
Morgan Stanley increased its Allogene Therapeutics (ALLO) stake by 352% in Q2 2026, buying an estimated $7.71M and bringing the position to 4,509,962 shares worth $9.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3739.
Morgan Stanley first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $29.5M in Q2 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- Morgan Stanley held 4,509,962 shares of Allogene Therapeutics worth $9.38M as of Q2 2026.
- Morgan Stanley bought 3,511,117 Allogene Therapeutics shares in Q2 2026, an estimated $7.71M.
- Allogene Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3739 holding.
- Morgan Stanley first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- Morgan Stanley's Allogene Therapeutics position peaked at $29.5M in Q2 2021.
- 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.